$Mega Ophthalmology-B (06622.HK) $Announced, the company and Visus Therapeutics, Inc. An agreement may be reached for the development and commercialization of BRIMOCHOL PF and Carbachol PF in the Greater and Central Asia, South Asia and designated South Asia.
It means that Visus, as a health care company in bed service, is focusing on the development of new ophthalmic practices to improve the health of people around the world. BRIMOCHOLPF and Carbacho PF are new preservative-free products and will be long-lasting daily eye drops that are losing the brachytherapy power of presbyopia.
In accordance with the terms of the agreement, the company shall conduct the development and supervision and approval of BRIMOCHOL PF and Carbachol PF in designated areas, and then carry out commercial activities for such products. The company will pay $15 million in advance and may pay up to $115 million at various regulatory, commercialization and sale milestones. The company will quickly finalize the required bed specifications and launch products by making use of the advanced bed development experience and planning of the phase 3 study currently being recruited by Visus.